I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

On April 5, 2024 I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, reported that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024 (Press release, I-Mab Biopharma, APR 5, 2024, View Source [SID1234641824]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

23rd Annual Needham Virtual Healthcare Conference

Presentation Time

Thursday, April 11 at 10:15 a.m. EST

Presenters

Raj Kannan, CEO; John Hayslip CMO

Webcast link

Here

Meetings

One-on-one and small group meetings: April 11, 2024

Management
Participants

Raj Kannan, CEO

Joe Skelton, CFO

John Hayslip, CMO
Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab’s IR website
at View Source

For more information, please contact your Needham representative.